After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Iovance Biotherapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Iovance Biotherapeutics Inc is $3.27B. A total of 3.57 million shares were traded on the day, compared to an average of 9.13M shares.
In the most recent transaction, Rothbaum Wayne P. bought 5,000,000 shares of IOVA for 9.15 per share on Feb 20 ’24. After the transaction, the Director now owns 28,067,333 company shares. In a previous transaction on Feb 20 ’24, MCPEAK MERRILL A bought 250,000 shares at 9.15 per share. IOVA shares that Director owns now total 320,150.
Among the insiders who bought shares, Dukes Iain D. acquired of 32,000 shares on Feb 20 ’24 at a per-share price of $9.15. This resulted in the Director holding 54,000 shares of IOVA after the transaction. In another insider transaction, MCPEAK MERRILL A bought 10,000 shares at $5.56 per share on Sep 18 ’23. Company shares held by the Director now total 248,633.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, IOVA has a high of $18.33 and a low of $3.21.
As of this writing, IOVA has an earnings estimate of $Sunnova Energy International In per share for the current quarter. EPS was calculated based on a consensus of Iovance Biotherapeutics, Inc. estimates, with a high estimate of $Inventiva S.A. – American Depos per share and a lower estimate of $Innoviva, Inc..
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. IOVA’s latest balance sheet shows that the firm has $504.41M in Cash & Short Term Investments as of fiscal 2021. There were $71.53M in debt and $89.20M in liabilities at the time. Its Book Value Per Share was $2.28, while its Total Shareholder’s Equity was $621.66M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IOVA is Buy with a score of 4.86.
